I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 28

Br J Dermatol

Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Controlled,


Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour J-P, Ghislain P-D, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K
Br J Dermatol. 2022 Apr 28.
PMID: 35484697.


Baricitinib, an oral selective Janus Kinase (JAK) 1 and JAK 2 inhibitor, was shown to improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD).